Literature DB >> 29963395

Pattern, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma: how do they matter?

Charing C N Chong1.   

Abstract

Entities:  

Year:  2018        PMID： 29963395      PMCID： PMC5994442          DOI： 10.21037/jovs.2018.05.14

Source DB:  PubMed          Journal:  J Vis Surg        ISSN： 2221-2965


× No keyword cloud information.
  9 in total

Review 1.  Adjuvant treatment for pancreatic ductal carcinoma.

Authors:  T Macarulla; T Fernández; M E Gallardo; O Hernando; A M López; M Hidalgo
Journal:  Clin Transl Oncol       Date:  2017-06-21       Impact factor: 3.405

Review 2.  Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.

Authors:  Wei-Chih Liao; Kuo-Liong Chien; Yu-Lin Lin; Ming-Shiang Wu; Jaw-Town Lin; Hsiu-Po Wang; Yu-Kang Tu
Journal:  Lancet Oncol       Date:  2013-09-12       Impact factor: 41.316

3.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Neda Rezaee; Wenchuan Wu; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Lei Zheng; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

Review 4.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma.

Authors:  M Elshaer; G Gravante; M Kosmin; A Riaz; A Al-Bahrani
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

5.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Authors:  John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler
Journal:  JAMA       Date:  2010-09-08       Impact factor: 56.272

6.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz
Journal:  J Clin Oncol       Date:  2017-04-11       Impact factor: 44.544

7.  Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis.

Authors:  Mark B Slidell; David C Chang; John L Cameron; Christopher Wolfgang; Joseph M Herman; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

8.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

9.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.